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The impact of efﬂuent wastewaters from four different hospitals: a university (1456 beds), a general (350 beds), a pediatric (110 beds) and a maternity 
hospital (96 beds), which are conveyed to the same wastewater treatment plant (WWTP), was evaluated in the receiving urban wastewaters. The occurrence of 
78 pharma- ceuticals belonging to several therapeutic classes was assessed in hospital efﬂuents and WWTP wastewaters (inﬂuent and efﬂuent) as well as the 
contribution of each hospital in WWTP inﬂuent in terms of pharmaceu- tical load. Results indicate that pharmaceuticals are widespread pollutants in both 
hospital and urban waste- waters. The contribution of hospitals to the input of pharmaceuticals in urban wastewaters widely varies, 
according to their dimension. The estimated total mass loadings were 306 g d− 1 for the university hospital, 
155 g d− 1 for the general one, 14 g d−1 for the pediatric hospital and 1.5 g d− 1 for the maternity hospital, showing that the biggest hospitals have a greater 
contribution to the total mass load of pharmaceuticals. Fur- thermore, analysis of individual contributions of each therapeutic group showed that NSAIDs, 
analgesics and antibiotics are among the groups with the highest  inputs. 
Removal efﬁciency can go from over 90% for pharmaceuticals like acetaminophen and ibuprofen to not removal for β-blockers and salbutamol. Total 
mass load of pharmaceuticals into receiving surface waters was estimated between 5 and 14  g/d/1000   inhabitants. 
Finally, the environmental risk posed by pharmaceuticals detected in hospital and WWTP efﬂuents was assessed by means of hazard quotients toward 
different trophic levels (algae, daphnids and ﬁsh). Several pharmaceuticals present in the different matrices were identiﬁed as potentially hazardous to 
aquatic organ- isms, showing that especial attention should be paid to antibiotics such as ciproﬂoxacin, oﬂoxacin, sulfameth- oxazole, azithromycin and 
clarithromycin, since their hazard quotients in WWTP efﬂuent revealed that they could pose an ecotoxicological risk to   algae. 
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1. Introduction 
 
Over the last decades, the worldwide consumption of pharmaceu- 
ticals has increased as well as their detection in wastewaters and 
 
 
surface waters, which represents a major concern in terms of their 
potential impact on the environment and human health. Wastewaters 
have been pointed out as the main route of entry of pharmaceuticals 
into the environment (Daughton and Ruhoy, 2009), since they gath- 
er the residues excreted after ingestion, which are excreted in urine 
and feces, either as unchanged compounds or metabolites. Several 
studies  pointed  out that  Wastewater  Treatment Plants (WWTPs) 
 
 are not able to completely remove pharmaceuticals (Behera et al., 
2011; Gracia-Lor et al., 2012; Jelic et al., 2011; Kosma et al., 2010; 
Zorita et al., 2009). Besides urban wastewaters, hospital wastewaters 
have also stood up as an important environmental exposure pathway 
of pharmaceuticals (Verlicchi et al., 2010b). 
Due to their speciﬁc nature, it is expected that hospital efﬂuents 
present a mixture of compounds, including not only pharmaceuticals 
and their metabolites, but also diagnostic agents, disinfectants, among 
others, resulting from diagnostic, laboratory and research activities 
and principally from medicine excretion from patients (Verlicchi et al., 
2010b). Consumption, use and application of pharmaceuticals in a hos- 
pital may vary over the year and from country to country (Schuster 
et al., 2008), due to the predominance of diseases and to the hospital 
activity, as well as to the local list of pharmaceuticals suggested for 
the treatment of different diseases. These changes will have impact on 
pharmaceuticals detected in hospital efﬂuents, since they are closely 
related with the substances that are being administered in a certain 
hospital as well as their quantities. Several authors have shown the 
presence of pharmaceuticals in hospital wastewaters (Gómez et al., 
2006; Lin and Tsai, 2009; Sim et al., 2011; Verlicchi et al., 2012a; 
Weissbrodt et al., 2009). Furthermore, hospital efﬂuents also play an 
important role in the introduction of pathogens into public wastewa- 
ters, especially concerning multi-resistant bacteria, contributing to the 
spread of antibiotic resistance into the environment (Kümmerer, 2009). 
Hospitals generate different quantities of wastewaters depending 
on factors like number of beds, hospital age, general services present 
inside the structure (kitchen, laundry, etc.), number and types of 
wards and units, institution management policies, cultural and geo- 
graphical factors, among others (Verlicchi et al., 2010b). Usually hos- 
pital efﬂuents are directly discharged into public sewer network, 
being co-treated with domestic wastewaters in municipal WWTPs. 
This practice has been questioned by some authors (Pauwels and 
Verstraete, 2006; Verlicchi et al., 2012a), who suggested the adoption 
of a more dedicated treatment for hospital efﬂuents before being 
discharged into public wastewaters and then both urban and hospital 
wastewaters would be subsequently treated in WWTPs (Pauwels and 
Verstraete, 2006; Verlicchi et al., 2010a). This approach has beneﬁts 
like avoiding the dilution of hospital wastewaters with urban waste- 
waters, which may result in the inhibition of biomass and reduction 
of removal efﬁciency in WWTPs, as well as to avoid losses into the 
environment due to sewer leakage and combined sewer overﬂows 
(Kovalova et al., 2012). At the same time, it is possible to avoid the 
spread of multi-antibiotic resistant bacteria (Kümmerer, 2009) and 
the input of chemical substances (pharmaceuticals, diagnostic agents, 
etc.) that in some cases are genotoxic (Gupta et al., 2009). 
Several monitoring studies have reported the presence of pharma- 
ceuticals in urban wastewaters (Al-Rifai et al., 2007; Brown et al., 
2006; Bueno et al., 2012; Gracia-Lor et al., 2011; Gros et al., 2006; 
Pedrouzo et al., 2011) and surface waters (Daneshvar et al., 2010; 
González Alonso et al., 2010; Kolpin et al., 2002; Martín et al., 2011; 
Spongberg et al., 2011; Vystavna et al., 2012). Nevertheless, few 
data is available on the contribution of hospital efﬂuents towards the 
load of pharmaceuticals in WWTPs (Beier et al., 2011; Langford and 
Thomas, 2009; Ort et al., 2010; Thomas et al., 2007; Verlicchi et al., 
2012a). At the same time, available data regarding the environmental 
risk posed by hospital efﬂuents to aquatic organisms is still sparse 
and often limited to predicted (Escher et al., 2011; Souza et al., 
2009) rather than measured concentrations (Verlicchi et al., 2012a). 
Due to their bioactive intrinsic properties, pharmaceuticals are 
recognized as being able to cause potential effects in aquatic organ- 
isms; therefore environmental risk assessment (ERA) studies are 
recommended, in order to consider the potential effect of pharmaceu- 
ticals at their exposure levels (von der Ohe et al., 2011). According to 
the guidelines set out by the European Medicines Agency (EMA), new 
pharmaceuticals require an ERA, which is assessed in a step-wise ap- 
proach, divided in two phases. In Phase I, environmental exposure of 
the pharmaceuticals is estimated and if their predicted environmental 
concentration (PEC) exceeds a threshold safety value of 10 ng L− 1, 
Phase II studies are required, in order to assess their ecotoxicological 
potential (EMEA, 2006). 
In this context, the aim of the present work was to monitor the oc- 
currence of 78 pharmaceuticals of major human consumption in four 
hospitals located in Coimbra (Portugal) with different capacities, 
wards and units, namely a university hospital (1456 beds), a general 
hospital (350 beds), a pediatric hospital (110 beds) and a maternity 
hospital (96 beds), as well as in the inﬂuent and efﬂuent wastewaters 
of the WWTP that receives and co-treats their wastewaters. The im- 
pact and individual contribution of each hospital to the load of phar- 
maceuticals into the receiving urban wastewaters was evaluated, 
being one of the few studies that embraced a high number of com- 
pounds belonging to several therapeutic classes. In addition, removal 
efﬁciency for all target compounds was also evaluated in WWTP. 
Finally, the potential ecotoxicological risk posed by pharmaceuticals 
to aquatic organisms when exposed to the studied hospital and 
WWTP efﬂuents was assessed and prioritization lists of potentially 
hazardous pharmaceuticals that should be included in monitoring 
programs and that might be considered for inclusion in future regula- 
tions were established. 
 
2. Materials and methods 
 
2.1. Sampling site, sample collection and sample pre-treatment 
 
Efﬂuents from four hospitals with different dimensions, units and 
wards located in Coimbra (Portugal) were sampled in this study, to- 
gether with the inﬂuent and efﬂuent of the receiving WWTP. Studied 
hospitals included: 
- University hospital: large hospital with 1456 beds and with a broad 
range of clinical and services and medical specialities as well as a 
center of research. It serves a population of approximately 430,000 
inhabitants and it is also a reference hospital for the center region 
of Portugal; 
- General hospital: medium-sized hospital with 350 beds and thir- 
teen main wards. It serves a population of approximately 369,000 
inhabitants; 
- Pediatric hospital: small hospital with 110 beds and nine main 
wards. It serves a population of approximately 90,000 inhabitants 
and it is a reference hospital that supports pediatric units of hospi- 
tals located in the center region of Portugal; 
- Maternity: small hospital with 96 beds, not including the baby unit, 
and three main wards, namely gynecology, obstetrics and neonatol- 
ogy. It serves a population of approximately 507,000 inhabitants 
(women). 
The WWTP is designed for 213,000 population equivalent and it 
has a primary and secondary treatment operating with trickling ﬁlters. 
The WWTP receives urban wastewaters (including domestic waste- 
waters and hospital efﬂuents — from the four mentioned hospitals) 
combined with rain waters. The biological treatment is performed by 
four trickling ﬁlters that work in parallel. They are 3 m high and 
36 m in diameter, having a unitary volume of 3030 m3. 
Sampling campaigns were performed between February 2011 and 
May 2011, embracing a total of nine sampling periods for hospitals 
and seven for WWTP (inﬂuent and efﬂuent). Samples from hospital 
efﬂuents and WWTP wastewaters were collected in the same days, 
with the exception of two days where it was only possible to collect 
samples from hospital wastewaters (namely 28th March 2011 and 
4th April 2011). Wastewater samples were collected in amber glass 
bottles previously rinsed with ultra-pure water as grab samples to 
hospital efﬂuents, which were all collected at the same time frame 
(10–11 a.m.), and time proportional 24-h composite samples to 
WWTP inﬂuent and efﬂuent. Samples were kept refrigerated (± 4 °C) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
Range of concentrations and mean concentration (± standard deviation), expressed in ng L
− 1
, of pharmaceuticals in hospital efﬂuents and in WWTP inﬂuent and   efﬂuent. 
 
 
Therapeutic group Compound University hospital General hospital Pediatric hospital Maternity hospital WWTP inﬂuent WWTP efﬂuent 
 
 
Analgesics and 
anti-inﬂammatories 
 
 
 
 
 
 
 
 
Lipid regulators 
and cholesterol 
lowering statin 
drugs 
 
Psychiatric drugs 
 
 
 
 
 
 
 
 
Histamine H1 
receptors 
antagonists 
Histamine H2 
receptors 
antagonists 
 
 
 Range Mean ± SD  Range Mean ± SD  Range Mean ± SD  Range Mean ± SD  Range Mean ± SD  Range Mean ± SD  
Ketoprofen bMQL–199 99.3 ± 66.3  143–3250 1107 ± 1269  83.6–180 124 ± 29  79.3–264 146 ± 66  289–589 458 ± 112  158–320 218 ± 52  
Naproxen 45.4–6042 1837 ± 2057  bMDL–4046 608 ± 1293  bMQL–5625 674 ± 1857  36.5–1638 504 ± 628  8.84–1617 741 ± 522  bMQL–774 303 ± 275  
Ibuprofen 232–5815 1965 ± 2082  237–11,333 3082 ± 4200  1263–38,148 7090 ± 11,995  1952–16,630 7728 ± 5286  bMDL–4926 1596 ± 1715  bMQL–369 119 ± 136  
Indomethacine n.d.–bMQL bMDL  n.d.–150 bMQL  n.d. n.d.  n.d.–79.5 bMDL  bMDL–51.0 bMDL  bMDL–bMQL bMDL  
Acetaminophen 13,029– 27,700 ±  12,557– 24,687 ±  2271–57,143 18,235 ±  211–13,986 9211 ± 4629  80.7–9286 2463 ± 3454  83.1–106 96.1 ± 8.1  
 58,857 16,107  47,143 12,201   15,503           
Salicylic acid 383–2817 1822 ± 825  bMDL–2272 1255 ± 806  6.89–4681 1256 ± 1546  72.2–4624 1343 ± 1486  bMDL–257 51.8 ± 92.6  n.d.–bMDL bMDL  
Diclofenac bMQL–189 80.8 ± 59.9  bMQL–63.5 bMQL  bMQL–169 46.6 ± 47.7  bMQL–103 47.0 ± 28.4  bMQL–269 69.7 ± 89.4  24.6–83.1 42.9 ± 19.5  
Phenazone 60.5–271 121 ± 73  51.7–146 84.4 ± 27.3  bMDL–10.4 bMQL  bMDL–64.4 14.1 ± 20.1  11.1–43.8 25.7 ± 12.5  12.6–52.9 29.5 ± 12.9  
Propyphenazone bMDL–1.72 bMQL  bMDL–1.47 bMQL  bMDL–1.53 bMQL  n.d.–bMQL bMDL  bMDL–bMQL bMDL  bMDL–bMQL bMQL  
Piroxicam n.d.–51.2 9.25 ± 19.0  n.d.–bMDL bMDL  n.d.–bMQL bMDL  n.d.–bMQL bMDL  bMDL–bMQL bMQL  bMDL bMDL  
Tenoxicam n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d.–bMDL bMDL  
Meloxicam n.d. n.d.  n.d.–b MDL bMDL  n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d.  
Oxycodone n.d.–bMDL bMDL  n.d.–bMDL bMDL  n.d.–23.5 bMQL  bMDL–12.9 bMQL  bMDL bMDL  bMDL bMDL  
Codeine 8.08–2837 467 ± 914  9.58–1006 295 ± 337  2.68–429 67.1 ± 140  3.49–2760 404 ± 896  153–283 206 ± 48  16.9–261 138 ± 86  
Bezaﬁbrate bMDL–1350 258 ± 452  bMDL–659 86.9 ± 216  n.d.–17.6 bMQL  n.d.–242 76.2 ± 87.3  382–623 490 ± 93  93.8–635 409 ± 214  
Gemﬁbrozil n.d.–285 32.8 ± 94.5  n.d. n.d.  n.d.–1126 125 ± 375  n.d.–224 38.6 ± 72.8  n.d.–22.5 bMQL  n.d.–bMQL bMDL  
Pravastatin bMQL–1200 305 ± 368  bMDL–332 75.5 ± 105  n.d.–2086 306 ± 673  n.d.–b MQL bMDL  124–327 218 ± 72  118–395 239 ± 111  
Fluvastatin n.d.–27.8 bMQL  n.d.–bMDL bMDL  n.d.–bMDL bMDL  n.d.–bMDL bMDL  n.d.–bMDL bMDL  n.d. n.d.  
Atorvastatin n.d.–60.0 9.86 ± 19.9  n.d. n.d.  n.d. n.d.  n.d.–65.1 13.1 ± 24.1  n.d.–bMQL bMDL  n.d. n.d.  
Carbamazepine 428–1050 771 ± 213  128–1123 650 ± 371  19.3–2042 295 ± 658  bMQL–344 64.5 ± 112  437–673 565 ± 74  364–496 460 ± 45  
Acridone⁎ n.d. n.d.  n.d. n.d.  n.d.–2.86 bMQL  n.d. n.d.  n.d.–bMDL bMDL  n.d.–bMDL bMDL  
Sertraline bMDL–bMQL bMDL  bMDL bMDL  bMDL–bMQL bMDL  bMDL–bMQL bMDL  bMDL–bMQL bMQL  n.d.–bMQL bMQL  
Citalopram 31.0–232 110 ± 86  9.43–122 58.3 ± 45.2  11.4–888 196 ± 335  11.2–457 145 ± 162  12.7–34.3 23.3 ± 7.8  17.0–49.1 34.0 ± 11.5  
Venlafaxine 81.3–880 325 ± 310  53.3–662 227 ± 194  13.0–972 245 ± 319  38.5–1914 545 ± 619  68.0–268 181 ± 79  184–322 272 ± 54  
Olanzapine 1.62–824 236 ± 267  bMQL–102 29.3 ± 35.6  n.d.–303 38.3 ± 99.4  n.d.–9.97 1.71 ± 3.58  n.d.–15.3 4.52 ± 6.23  15.0–36.1 26.2 ± 8.4  
Trazodone 5.37–51.1 16.2 ± 13.8  bMQL–31.1 11.4 ± 9.6  bMQL–36.6 7.86 ± 11.1  bMDL–36.9 12.5 ± 13.8  3.06–11.1 6.72 ± 2.72  bMQL–6.37 4.03 ± 1.84  
Fluoxetine 34.8–105 70.1 ± 37.6  18.3–43.6 31.0 ± 9.3  n.d.–44.5 19.3 ± 15.6  n.d.–128 36.7 ± 46.3  bMDL–29.7 bMQL  n.d.–bMQL bMDL  
Norﬂuoxetine⁎ bMQL–49.1 15.3 ± 16.7  bMQL–40.9 24.7 ± 13.3  bMQL–33.4 10.3 ± 8.9  bMQL–85.1 26.1 ± 31.9  45.1–226 112 ± 67  bMDL–99.6 36.1 ± 38.4  
Paroxetine bMDL–bMQL bMDL  bMDL bMDL  bMDL bMDL  bMDL bMDL  bMDL bMDL  bMDL–bMQL bMQL  
Diazepam 12.2–31.1 18.5 ± 6.9  bMDL–29.6 10.5 ± 7.8  bMDL–31.9 bMQL  bMQL–49.1 17.7 ± 18.1  bMQL–7.63 6.46 ± 0.84  6.53–8.81 7.16 ± 0.82  
Lorazepam 107–1325 441 ± 374  151–520 308 ± 142  28.2–320 110 ± 94  43.9–551 289 ± 165  221–446 299 ± 81  175–347 294 ± 59  
Alprazolam 37.5–81.5 44.9 ± 13.9  42.2–168 106 ± 40  6.87–143 34.3 ± 42.5  4.58–96.7 46.5 ± 26.0  19.1–49.1 32.3 ± 11.1  11.3–33.5 27.5 ± 7.9  
Loratadine n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d.  
Desloratadine⁎ n.d.–10.2 2.66 ± 3.33  n.d.–0.713 bMQL  n.d.–1.07 bMQL  n.d.–1.31 0.224 ± 0.469  n.d. n.d.  n.d. n.d.  
Ranitidine 31.3–12,240 2152 ± 4171  255–19,840 4164 ± 6366  16.2–856 115 ± 278  44.4–3240 477 ± 1046  41.6–359 211 ± 106  31.7–313 149 ± 98  
Famotidine bMQL–14.5 4.11 ± 4.38  bMQL–212 26.1 ± 69.7  bMQL–1.32 bMQL  bMQL–2.58 bMQL  bMQL–3.96 2.01 ± 1.07  1.36–2.82 1.99 ± 0.48  
Cimetidine bMDL–24.9 4.55 ± 8.20  2.49–479 58.4 ± 158  n.d.–1.80 bMDL  n.d.–2.47 bMQL  2.40–14.6 7.07 ± 4.20  2.00–11.9 7.40 ± 3.41  
 
  
 
β–Blockers Atenolol 76.3–2000 706 ± 575 172–1171 595 ± 361 8.55–8037 1069 ± 2628 45.5–5908 1063 ± 1852 361–751 522 ± 132 411–782 600 ± 152 
 Sotalol bMDL–345 89.1 ± 122 23.7–142 56.9 ± 36.9 n.d.–bMDL bMDL n.d.–172 20.5 ± 56.9 85.7–144 117 ± 24 83.1–186 154 ± 34 
 Propranolol bMQL–53.6 21.3 ± 16.9 4.19–81.0 18.0 ± 24.7 n.d.–812 98.9 ± 268 6.36–243 66.6 ± 83.7 2.61–23.9 8.98 ± 8.05 4.28–10.6 8.27 ± 2.07 
 Metoprolol n.d.–280 35.6 ± 92.0 bMQL–441 59.9 ± 144 n.d.–148 18.8 ± 48.5 n.d.–5.29 bMQL bMQL–15.2 bMQL 5.50–18.4 11.9 ± 4.28 
 Nadolol n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.–2.14 bMQL n.d. n.d. 
 Carazolol 6.05–7.37 6.63 ± 0.39 5.79–6.39 6.01 ± 0.19 5.66–6.89 6.19 ± 0.44 5.68–6.87 6.11 ± 0.44 2.82–3.11 2.91 ± 0.11 bMQL bMQL 
Diuretic Hydrochlorothiazide 692–810 767 ± 41 590–863 764 ± 102 223–825 565 ± 238 239–997 518 ± 257 359–424 393 ± 22 223–233 229 ± 4 
 Furosemide 4763–22,326 12,014 ± 6337 2363–21,488 11,121 ± 5671 535–32,558 5444 ± 10,241 434–9953 3574 ± 3652 1591–4577 2726 ± 1043 267–2214 1183 ± 609 
 Torasemide n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Antidiabetic Metformin 18.6–2844 972 ± 859 484–3836 1346 ± 1105 16.1–716 174 ± 242 bMQL–4040 1163 ± 1329 bMQL–1568 720 ± 551 3.87–299 164 ± 124 
 Glibenclamide n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Antihypertensives Amlodipine bMQL–195 93.9 ± 56.9 bMQL–101 37.8 ± 27.6 bMQL–45.5 bMQL bMDL–110 36.5 ± 31.8 14.9–85.7 48.5 ± 24.6 bMQL–78.7 41.4 ± 30.1 
 Losartan 72.0–910 259 ± 264 59.0–433 178 ± 113 bMDL–333 141 ± 108 bMQL–257 92.8 ± 85.0 90.0–658 237 ± 205 bMQL–364 143 ± 106 
 Irbesartan 90.0–2120 539 ± 620 18.4–1850 520 ± 562 bMDL–1830 491 ± 596 39.9–3860 670 ± 1206 278–1170 591 ± 317 116–790 410 ± 237 
 Valsartan 902–19,822 8936 ± 7423 407–4489 1562 ± 1327 104–11,733 1873 ± 3774 280–7822 1846 ± 2369 2956–8400 5117 ± 2009 20.8–4860 2377 ± 2100 
Antiplatelet agent Clopidogrel 37.1–396 162 ± 121 33.3–175 98.1 ± 44.8 3.03–199 32.6 ± 62.7 2.39–184 31.4 ± 59.6 2.57–53.4 20.6 ± 20.0 4.21–16.8 11.1 ± 4.3 
Prostatic hyperplasia Tamsulosin 2.26–3.20 2.62 ± 0.31 1.69–2.37 1.99 ± 0.26 1.62–2.24 1.93 ± 0.22 1.47–2.02 1.62 ± 0.17 0.781–1.37 1.04 ± 0.23 bMQL–0.872 0.719 ± 0.143 
β-Agonist Salbutamol n.d.–2595 383 ± 832 56.1–199 136 ± 51 11.9–279 77.6 ± 88.9 n.d.–43.4 6.78 ± 14.4 0.967–12.1 7.34 ± 3.62 4.43–26.8 16.1 ± 7.5 
Anticoagulant Warfarin 3.57–8.28 6.17 ± 1.80 2.21–8.02 4.50 ± 2.01 bMQL–2.85 1.42 ± 0.71 bMQL–2.47 1.54 ± 0.73 bMQL–7.10 3.55 ± 1.75 1.56–3.87 2.42 ± 0.76 
X-ray contrast agent Iopromide 66,286– 19,5683 ± 50,229– 26,0908 ± 880–24,743 7493 ± 7606 205–1243 461 ± 341 23,543– 79,527 ± 33,885– 49,286 ± 
  550,857 168,147 611,429 216,851     164,000 46,533 85,000 16,933 
Antihelmintics Albendazole n.d.–bMQL bMDL n.d.–28.3 3.38 ± 9.37 n.d.–bMDL bMDL n.d.–bMQL bMDL n.d.–1.79 0.526 ± 0.739 n.d. n.d. 
 Thiabendazole n.d.–9.77 bMQL n.d.–494 58.2 ± 164 n.d.–1746 398 ± 572 n.d.–97.7 31.0 ± 39.9 n.d.–15.3 2.77 ± 5.75 0.493–12.1 4.95 ± 4.18 
 Levamisole n.d.–39.5 5.82 ± 12.9 n.d. n.d. n.d.–182 20.4 ± 60.7 n.d.–74.3 25.5 ± 30.2 6.96–24.0 11.7 ± 5.9 8.72–31.5 19.1 ± 7.9 
Synthetic glucocorticoid Dexamethasone 72.4–352 127 ± 87 bMQL–61.8 28.4 ± 19.5 n.d.–31.0 bMQL bMDL–278 66.9 ± 98.9 n.d.–bMQL bMQL bMDL–bMQL bMQL 
Sedation and muscle Xylazine n.d. n.d. n.d. n.d. n.d.–13.6 bMQL n.d.–24.4 bMQL n.d. n.d. n.d. n.d. 
relaxation              
Tranquilizer Azaperone bMDL–2.70 bMQL bMDL–3.87 bMQL bMDL–bMQL bMQL n.d.–bMQL bMDL bMDL bMDL n.d.–bMDL bMDL 
 Azaperol⁎ n.d.–bMQL bMDL n.d.–bMDL bMDL n.d.–bMDL bMDL n.d. n.d. n.d.–bMDL bMDL n.d.–bMDL bMDL 
Antibiotics Erythromycin bMQL–1075 209 ± 355 n.d.–22.2 bMQL n.d.–913 108 ± 302 47.8–7545 1407 ± 2350 9.64–220 92.7 ± 77.9 20.4–134 71.2 ± 40.6 
 Azithromycin 1227–7351 3748 ± 2331 89.2–4492 1889 ± 1299 bMQL–376 85.8 ± 116 bMQL–2665 840 ± 917 79.7–295 186 ± 79 93.7–297 171 ± 68 
 Clarithromycin 2.56–199 62.6 ± 71.6 n.d.–45.6 7.56 ± 15.6 n.d.–960 135 ± 312 n.d.–165 32.5 ± 59.0 n.d.–52.3 22.2 ± 17.8 12.0–40.0 22.4 ± 11.4 
 Tetracycline n.d.–bMDL bMDL n.d.–bMDL bMDL n.d.–bMDL bMDL n.d.–bMDL bMDL bMDL–32.3 12.1 ± 12.7 bMDL–22.8 bMQL 
 Oﬂoxacin 3135–24,811 12,222 ± 6786 1986–12,865 7302 ± 3741 n.d.–662 104 ± 219 n.d.–bMQL bMDL 51.9–4986 946 ± 1790 110–366 233 ± 79 
 Ciproﬂoxacin 2259–38,689 11,624 ± 11,340 457–13,344 3673 ± 3786 120–1334 503 ± 443 101–2000 572 ± 574 107–330 221 ± 88 127–1396 369 ± 455 
 Sulfamethoxazole 307–8714 3015 ± 3012 191–5524 1897 ± 1656 41.0–1288 401 ± 447 n.d.–695 89.6 ± 230 529–1662 912 ± 391 340–1679 950 ± 460 
 Trimethoprim 837–3963 1849 ± 1272 30.5–1182 528 ± 431 12.5–1089 337 ± 340 n.d.–122 13.5 ± 40.5 n.d.–360 124 ± 131 66.6–299 167 ± 78 
 Metronidazole n.d.–12,315 1638 ± 4037 bMDL–1569 192 ± 517 bMQL–4315 586 ± 1410 bMDL–5008 751 ± 1633 bMDL–113 51.1 ± 49.8 19.4–83.5 51.1 ± 21.1 
 Metronidazole–OH⁎ n.d.–11,344 1604 ± 3690 n.d.–2125 261 ± 700 n.d.–523 121 ± 191 n.d.–990 229 ± 350 n.d.–145 62.9 ± 69.0 64.7–158 102 ± 33 
 Ronidazole n.d.–bMQL bMDL n.d.–bMQL bMDL n.d.–bMQL bMDL n.d.–bMQL bMDL n.d.–bMDL bMDL n.d.–bMDL bMDL 
Calcium channel Diltiazem 416–1470 814 ± 348 161–886 414 ± 263 15.5–174 58.4 ± 50.5 bMQL–346 50.9 ± 111 74.3–489 283 ± 167 154–231 189 ± 33 
blockers Verapamil 5.68–67.2 14.2 ± 19.9 4.14–12.0 6.80 ± 2.81 4.00–5.83 4.78 ± 0.56 4.17–6.55 5.21 ± 0.68 2.83–4.88 4.12 ± 0.76 1.22–3.04 2.20 ± 0.60 
 Norverapamil⁎ bMDL–5.13 bMQL n.d.–8.93 bMQL n.d.–bMQL bMDL n.d.–4.00 bMDL n.d.–0.908 bMQL n.d.–bMDL bMDL 
* Metabolites; b MDL — below method detection limit; b MQL — below method quantiﬁcation limit; n.d. — not detected. 
  
 
during the transport to the laboratory. Upon reception, samples were 
vacuum ﬁltered through 1.0 μm glass microﬁber ﬁlters (GF/C, Whatman, 
UK), followed by 0.45 μm nylon membrane ﬁlters (Whatman, UK) and 
stored at −20 °C, until extraction. As the suspended solids are removed 
during sample preparation, the measured concentrations of pharmaceu- 
ticals correspond to their dissolved fraction. 
 
2.2. Investigated pharmaceutical compounds 
 
In this study, a total of 78 pharmaceuticals belonging to 20 differ- 
ent therapeutic classes were studied. The list of selected therapeutic 
classes was as follows: analgesics and anti-inﬂammatories (14 com- 
pounds); lipid regulators and cholesterol lowering statin drugs (5 
compounds); psychiatric drugs (13 compounds); histamine H1 recep- 
tors antagonists (2 compounds); histamine H2 receptors antagonists 
(3 compounds); β-blockers (6 compounds); diuretics (3 compounds); 
oral antidiabetics (2 compounds); antihypertensives (4 compounds); 
antiplatelet agent (1 compound); prostatic hyperplasia (1 compound); 
β-agonist (1 compound); anticoagulant (1 compound); X-ray contrast 
agent (1 compound); antihelmintics (3 compounds); synthetic gluco- 
corticoid (1 compound); sedation and muscle relaxation (1 compound); 
tranquilizer (2 compounds); antibiotics (11 compounds); and calcium 
channel blockers (3 compounds). For more detailed information, see 
Table S1, Supporting information. 
 
2.3. Chemicals and reagents 
 
For more detailed information, see Supporting information. 
fragment ions for each compound, as described in detail elsewhere 
(Gros et al., 2012). Detailed information on the optimized mass spec- 
trometer parameters (two SRMs, collision energies, and ion ratio) for 
each investigated compound in negative and positive ionization 
modes as well as on the internal standards used for quantiﬁcation is 
given in Supporting information (Tables S1 and S4). 
 
2.5. Mass loading estimations 
 
Mass loadings of pharmaceuticals were calculated for each sam- 
pling period by multiplying individual concentrations of each pharma- 
ceutical found by the mean daily ﬂow rate of wastewater provided by 
the WWTP (Table S2, Supporting information). In the case of hospitals, 
their individual mass loadings were evaluated using the estimated 
daily water consumption data provided by the hospitals (Table S3, 
Supporting information). For the WWTP, loads were normalized by 
the population equivalent. 
Individual contribution of each hospital efﬂuent into the load of 
pharmaceuticals in the receiving WWTP was obtained by dividing 
the total mass load of the considered therapeutic group in the hos- 
pital efﬂuent by the total mass load of the same therapeutic group 
in the WWTP inﬂuent multiplied by 100. The total mass loads of 
each therapeutic group used to calculate the contribution of hospi- 
tals refers to the mean value of the seven sampling campaigns 
performed. 
Removal efﬁciency of pharmaceuticals was evaluated by means of 
Eq. (1): 
 
2.4. Analytical method 
  
  
 
Preparation and analysis of the samples was adapted from the 
protocols described in Gros et al. (2009, 2012). Brieﬂy, after ﬁltration, 
an appropriate volume of aqueous solution of 5% Na2EDTA was added 
to 200 mL of efﬂuent and 100 mL of inﬂuent wastewaters, and 50 mL 
of hospital efﬂuent, in order to achieve a ﬁnal Na2EDTA concentration 
of 0.1%. Afterwards, samples were pre-concentrated onto Oasis HLB 
cartridges (60 mg, 3 mL), previously conditioned with 5 mL of meth- 
anol and 5 mL of HPLC grade water, using a vacuum manifold system 
(Phenomenex, USA) at a ﬂow rate of approximately 5 mL min− 1. 
After that, cartridges were rinsed with 5 mL of HPLC grade water 
and dried under vacuum for 15–20 min, to remove excess of water. 
Finally, analytes were eluted with 6 mL of pure methanol at a ﬂow 
rate of 1 mL min− 1. Extracts were evaporated to dryness under a 
gentle stream of nitrogen and reconstituted with 1 mL of methanol/ 
water (10:90, v/v). Lastly, 10 μL o f a 1 ng μL− 1 standard mixture 
containing all isotopically labeled standards were added in the extract 
as internal standards. 
Instrumental analysis was performed in a Waters Acquity Ultra- 
Performance™ liquid chromatography system, equipped with two bi- 
nary pumps systems (Milford, MA, USA), and coupled to a 5500 
QTRAP hybrid triple quadrupole-linear ion trap mass spectrometer 
with a turbo Ion Spray source (Applied Biosystems, Foster City, CA, 
USA). Chromatographic separation was achieved using an Acquity 
HSS T3 column (50 × 2.1 mm i.d., 1.7 μm particle size) for the com- 
pounds analyzed under positive electrospray ionization (PI) and an 
Acquity BEH C18 column (50 × 2.1 mm i.d., 1.7 μm particle size) for 
the ones analyzed under negative electrospray ionization (NI), both 
purchased from Waters Corporation. For the analysis in PI mode, 
methanol was used as eluent A and 10 mM formic acid/ammonium 
formate (pH 3.2) as eluent B at a ﬂow rate of 0.5 mL min− 1, whereas 
the analysis in NI mode was carried out using acetonitrile as eluent A 
and 5 mM ammonium acetate/ammonia (pH 8) as eluent B at a ﬂow 
rate of 0.6 mL min− 1. For both modes, the injection volume was 5 μL. 
Quantiﬁcation of analytes was performed by SRM, monitoring two 
transitions between the precursor ion and the most    abundant 
where minf is the load of pharmaceutical in WWTP inﬂuent and meff 
is the load of pharmaceutical in WWTP efﬂuent. 
 
2.6. Environmental risk assessment 
 
Prioritization of pharmaceuticals based on environmental risk as- 
sessment was deﬁned regarding their hazard quotient (HQ), using 
three different trophic levels representatives of the aquatic ecosystem 
(algae, daphnids and ﬁsh). HQs were calculated according to EU 
guidelines (European Comission, 2003) as the quotient between mea- 
sured environmental concentration (MEC) and predicted no-effect 
concentration (PNEC), where the maximum individual concentrations 
of pharmaceuticals found in the different wastewaters were used as 
MEC. When the reported concentration was below the method quan- 
tiﬁcation limit (b MQL), half of the MQL value was considered (von der 
Ohe et al., 2011). PNEC values were estimated using the lowest acute 
ecotoxicological data reported in the literature (EC50 or LC50) for 
short term standard toxicity studies using three different species 
from several trophic levels (ﬁsh, Daphnia and algae) and applying 
an assessment factor (usually 1000) (European Comission, 2003), in 
order to take into account the extrapolation from inter- and intra- 
species variability in sensitivity (Sanderson et al., 2003). When no ex- 
perimental values were available, EC50 values estimated with ECOSAR 
(Sanderson et al., 2003) were used (Table S7, Supporting informa- 
tion). If HQ is equal or above 1 there is a potential environmental risk 
situation, whereas when values are lower than 1, no risk is expected 
(Straub, 2002). 
 
3. Results and discussion 
 
3.1. Occurrence of pharmaceuticals in hospital efﬂuents 
 
Table 1 presents the occurrence data of the selected pharmaceuti- 
cals in the efﬂuents of the four hospitals studied in this work, namely 
a university, a general, a pediatric and a maternity hospital. A similar 
 number of pharmaceuticals was detected in all hospitals, speciﬁcally 
67 compounds in the university and maternity hospitals, 63 in the 
pediatric one and 62 in the general one (Table 1). Only 7 out of   the 
78 pharmaceuticals studied (tenoxicam, meloxicam, loratadine, 
nadolol, torasemide, glibenclamide and tetracycline) had never been 
detected in any of the hospitals. However, differences in pharmaceu- 
tical concentrations between the efﬂuents of the four hospitals were 
observed, since those reﬂect the variation in pharmaceuticals con- 
sumption of each healthcare facility, which is strictly connected 
with their number of beds as well as the number and type of wards 
and units, and to the consumption patterns deﬁned by the National 
Guidelines for the Proper Use of Pharmaceuticals for the Different 
Diseases. Therefore, the highest concentrations were found in the ef- 
ﬂuents of the university and general hospitals rather than the other 
ones and different consumption patterns for the four hospitals could 
be established. Taking into account the relative concentration of phar- 
maceuticals for each hospital, it can be observed that in the pediatric 
and the maternity hospitals more than 50% of total pharmaceuticals 
belong to analgesic and anti-inﬂammatory drugs, which are by far 
much higher levels than those found in the university and the general 
hospitals (less than 15%). Diuretics also have an important pattern 
in pediatric and maternity hospitals with a relative percentage of 
the total concentration of approximately 12%. On the other hand, 
iopromide accounts for 65 and 75% of the total concentration of phar- 
maceuticals detected in university and general hospitals, respectively, 
in opposition to the low contribution in the other hospitals. Universi- 
ty hospital also has a more pronounced consumption of antibiotics 
(about 7%) than the other hospitals. 
Analgesics/anti-inﬂammatories, antibiotics and X-ray contrast agent 
are amongst the therapeutic groups most widely detected in hospital 
efﬂuents, as was previously reported by Verlicchi et al. (2010b). 
From all studied pharmaceuticals, the highest concentration was 
detected for the X-ray contrast agent iopromide in the general hospital 
(611,429 ng L−1), followed by the university one (550,857 ng L−1). 
Nevertheless, concentrations of one order of magnitude higher were 
reported in efﬂuents from a hospital in Switzerland (Weissbrodt et al., 
2009). 
Acetaminophen and ibuprofen are among the analgesics/ anti-
inﬂammatories pharmaceuticals with highest concentrations 
detected in  all  hospital  efﬂuents  (up  to  58,857 ng L− 1  and 
38,148 ng L− 1, respectively). Comparatively to previous ﬁndings, 
Thomas et al. (2007) reported higher levels of acetaminophen 
(329,852 ng L− 1) in the efﬂuents of hospitals from Oslo (Norway), 
while ibuprofen did not exceed 8957 ng L− 1.On the other hand, 
lower concentrations of these pharmaceuticals were detected in the 
efﬂuents of two Italian hospitals, where acetaminophen levels went 
from 1400 to 5900 ng L− 1 and ibuprofen from 380 to 3200 ng L− 1 
(Verlicchi et al., 2012a). Opposite to this trend, Sim et al. (2011) 
never detected acetaminophen or ibuprofen in efﬂuents from four 
general hospitals in Korea. These ﬁndings may be correlated with dif- 
ferences in pharmaceuticals consumption among countries. Another 
anti-inﬂammatory commonly detected in hospital efﬂuents is salicylic 
acid. In the present study it was found at levels ranging from b 2.7 to 
4681 ng L− 1 (Table 2), while in Greece its concentration reached 
14,600 ng L− 1 (Kosma et al., 2010) and in Italy did  not exceed 
2400 ng L− 1 (Verlicchi et al., 2012a). 
Among the analgesics opiates, codeine is one of the most often 
used in hospitals; therefore it was detected in the efﬂuents of the 
four hospitals at concentrations up to 2837 ng L− 1. These concentra- 
tions are in agreement with codeine levels previously reported in 
Italy (Verlicchi et al., 2012a), while in Taiwan its maximum concen- 
tration was 378 ng L− 1 (Lin et al., 2010). 
The highest concentrations of antibiotics were found in the 
university and general hospitals, being the most prevalent com- 
pounds the ﬂuoroquinolone antibiotics oﬂoxacin and ciproﬂoxacin 
(24,811 and 38,689 ng L− 1, respectively), followed by sulfamethoxa- 
zole (8714 ng L− 1) and azithromycin (7351 ng L− 1), in contrast to 
the maternity hospital where erythromycin was the most abundant 
antibiotic (7545 ng L− 1). Several studies have reported the presence 
of antibiotics in hospital efﬂuents, being the ﬂuoroquinolones among 
the most detected. For instance, the measured concentrations of cip- 
roﬂoxacin are in agreement with previous ﬁndings reported in litera- 
ture to hospital efﬂuents in Norway (up to 23,336 ng L− 1) (Thomas et 
al., 2007), Switzerland (31,980 ng L− 1) (Kovalova et al., 2012)   and 
 
 
Table 2 
Loads detected in both WWTP inﬂuent and efﬂuent (mg/d/1000 inhabitants) for the different therapeutic groups and removal efﬁciency, including all the seven sampling 
campaigns. 
Therapeutic group Load in WWTP inﬂuent 
(mg/d/1000 inhabitants) 
 
Load in WWTP efﬂuent 
(mg/d/1000  inhabitants) 
Removal efﬁciency (%) 
 
   
Range Mean Range Mean Range Mean 
 
NSAIDs 80–988 407 46–136 87 42–93 79 
Analgesics 74–1149 359 25–121 57 13–95 84 
Lipid regulators and cholesterol lowering statin agents 64–142 106 46–106 78 NE–61 26 
Psychiatric drugs 141–279 186 140–213 161 NE–24 13 
Histamine H2 receptor antagonists 6.9–44 33 7.1–38 20 NE–83 40 
β-blockers 63–159 98 74–132 106 NE–17 NE 
Diuretics 241–668 455 125–279 181 12–81 60 
Oral antidiabetic (metformin) 0.04–19 10 0.05–4.0 2.2 NE–99 77 
Antihypertensives 409–1340 892 66–694 352 NE–94 61 
Calcium channel blockers 10–91 49 19–42 27 NE–65 45 
Antibiotics 174–1612 512 229–362 294 NE–85 43 
- Fluoroquinolone antibiotics 19–1337 281 45–217 83 NE–95 70 
- Macrolide antibiotics 24–53 43 21–52 35 NE–60 19 
- Sulfametoxazole 75–199 135 57–201 120 NE–41 11 
- Trimethoprim n.d.–43 20 15–36 22 NE–20 NE 
- Others antibiotics 2.0–67 24 13–32 22 NE–58 7 
Antiplatelet agent (clopidogrel) 0.3–6.1 3.1 0.5–2.9 1.6 NE–69 48 
Prostatic hyperplasia (tamsulosin) 0.09–0.3 0.2 0.04–0.2 0.09 NE–71 46 
β-agonist (salbutamol) 0.1–1.7 1.1 1.1–3.2 1.9 NE–15 NE 
Anticoagulant (warfarin) 0.2–1.0 0.5 0.3–0.4 0.3 NE–59 28 
X-ray contrast agent  (iopromide) 6966–22,965 12,202 4394–11,902 7241 NE–61 41 
Antihelmintics 1.1–3.1 2.1 2.4–3.9 3.1 NE–7 NE 
Total load 9948–25,295 15,318 5339–13,719 8613   
n.d. — Not detected; NE — Not eliminated (compounds for which the concentrations found in WWTP efﬂuent were higher than the concentrations found in WWTP inﬂuent). 
 Italy (1400–26,000 ng L− 1) (Verlicchi et al., 2012a), while Duong et 
al. (2008) found lower concentrations  of  ciproﬂoxacin  (1100– 
10,900 ng L− 1) in Taiwan. On the other hand, higher levels were 
detected in a university hospital in Germany (up to 51,000 ng L− 1) 
(Ohlsen et al., 2003) and in Sweden (3600–101,000 ng L− 1) 
(Lindberg et al., 2004). However, for oﬂoxacin higher levels were 
detected in Italy (3300–37,000 ng L− 1) (Verlicchi et  al.,  2012a), 
USA (up to 35,500 ng L− 1) (Brown et al., 2006) and Germany (up 
to 31,000 ng L− 1) (Ohlsen et al., 2003), but not in Sweden (200– 
7600 ng L− 1) (Lindberg et al., 2004). Relatively to sulfamethoxazole, 
the concentrations found reaching up to 8714 ng L− 1, which  were, 
in general, higher than data reported in literature (Brown et al., 
2006; Kovalova et al., 2012; Ohlsen et al., 2003; Thomas et al., 2007; 
Verlicchi et al., 2012a). Nevertheless, levels up to 12,800 ng L− 1 
were detected in hospital efﬂuents in Sweden (Lindberg et al., 2004). 
Sim et al. (2011) studied the presence of different antibiotics in the 
efﬂuents of four general hospitals, in Korea, showing that only tri- 
methoprim had higher concentrations (95,100 ng L− 1) than those 
reported in the present study (3963 ng L− 1), while ciproﬂoxacin, 
sulfamethoxazole and erythromycin showed lower concentrations 
(up to 3080, 3840 and 470 ng L− 1, respectively). Moreover, Ohlsen 
et al. (2003) also determined the presence of several antibiotics in 
the efﬂuent of a university hospital in Würzburg (Germany), reporting 
concentrations of erythromycin (up to 6000 ng L− 1), which are in 
agreement with the present ﬁndings (up to 7545 ng L− 1 in the mater- 
nity hospital). 
Furosemide was the most prevalent diuretic at the four hospitals, 
being detected at concentrations from 434 ng L− 1 in maternity hos- 
pital to 32,558 ng L− 1 in pediatric hospital. In general, the studied 
hospitals presented higher concentrations of furosemide than those 
reported in Switzerland (2037 ng L− 1) (Kovalova et al., 2012) and 
in Italy (5300–18,000 ng L− 1) (Verlicchi et al., 2012a). In the case of 
antihypertensives, valsartan was the most predominant pharmaceuti- 
cal, with levels up to 19,822 ng L−1 in university hospital. Similar ﬁnd- 
ings were found in USA (14,572 ng L−1) (Nagarnaik et al., 2010), while 
in Switzerland lower concentrations were detected (3032 ng L−1) 
(Kovalova et al., 2012). 
Glibenclamide has been described as the oral antidiabetic most often 
used in hospitals (Verlicchi et al., 2010b) and its presence has been 
reported in their efﬂuents at concentrations from 50 to 110 ng L−1 
(Verlicchi et al., 2012a). Nevertheless, in this study only metformin 
was detected in hospital efﬂuents, rising levels up to 4040 ng L−1 in 
maternity hospital, which might be justiﬁed with the higher consump- 
tion rate of metformin among Portuguese population comparatively to 
glibenclamide (INFARMED, 2012). 
Among β-blockers, atenolol had the highest detected concentra- 
tions, reaching levels up to 8037 ng L− 1 in pediatric hospital. These 
values were higher than concentrations previously reported,  which 
showed the presence of atenolol in hospital efﬂuents of Italy (Verlicchi 
et al., 2012a), USA (Nagarnaik et al., 2010) and Switzerland (Kovalova 
et al., 2012) at levels up to 6600, 3166 and 2315 ng L−1, respectively. 
Ranitidine was the most abundant histamine H2 receptor antago- 
nist, being found in the general hospital at concentrations up to 
19,840 ng L− 1, which are one order of magnitude higher than those 
reported in Switzerland (Kovalova et al., 2012), Italy (Verlicchi et 
al., 2012a) and Spain (Gómez et al., 2006). 
Relatively to psychiatric drugs, they are one of the therapeutic 
groups with highest frequency of detection, though with low concen- 
trations (Table 1). Among them, carbamazepine, venlafaxine, loraze- 
pam and citalopram were the most representative compounds, being 
detected at concentrations up to 2042 ng L− 1 (pediatric hospital), 
1914 ng L− 1 (maternity hospital), 1325 ng L− 1 (university hospital) 
and 888 ng L− 1 (pediatric hospital), respectively. The levels of carba- 
mazepine reported in this study are in agreement with previous 
ﬁndings reported in Greece (up to 1900 ng L− 1) (Kosma et  al., 
2010). However, higher concentrations (up to 14,400 ng L− 1)    were 
detected in the efﬂuents of four general hospitals in Korea (Sim 
et al., 2011), while in Italy the levels of carbamazepine ranged from 
640 to 1200 ng L− 1 (Verlicchi et al., 2012a) and in USA did not exceed 
37 ng L− 1 (Nagarnaik et al., 2011). In what concern to lorazepam, 
lower concentrations (from 170 to 790 ng L− 1) were  reported in 
Italy (Verlicchi et al., 2012a). 
 
3.2. Occurrence of pharmaceuticals in urban wastewaters: loads, impact 
of hospital efﬂuents and removal efﬁciency of WWTP 
 
In order to evaluate the individual contribution of each hospital to 
the load of pharmaceuticals into the public sewer and the capability of 
the WWTP to remove them, wastewaters from the receiving WWTP 
were analyzed. 
The occurrence of pharmaceuticals in WWTP inﬂuent and efﬂuent 
followed a similar pattern to that one observed in hospitals, embrac- 
ing 65 and 61 compounds, respectively. However, pharmaceuticals 
belonging to histamine H1 receptor antagonists were never detected 
in WWTP wastewaters. Summarily, a total of 10 out of 78 pharmaceu- 
ticals were never detected in these matrices, namely tenoxicam, 
meloxicam, ﬂuvastatin, acridone, loratadine, desloratadine, torasemide, 
glibenclamide, xylazine and azaperol (Table 1). The total daily loads of 
pharmaceuticals per 1000 inhabitants for the most representative ther- 
apeutic groups, for WWTP inﬂuent and efﬂuent, is depicted in Fig. 1. 
Boxplots correspond to the addition of individual concentrations of 
each pharmaceutical belonging to a certain therapeutic group found in 
WWTP inﬂuent or efﬂuent and includes the seven sampling campaigns 
performed. Total mass loads detected were between 10 and 25 g/d/ 
1000 inhabitants for WWTP inﬂuent and from 5 to 14 g/d/1000 inhab- 
itants for WWTP efﬂuent (Table 2). These values are higher than those 
reported for WWTPs in Italy (Castiglioni et al., 2006), Spain (Gros et 
al., 2007) and Sweden (Zorita et al., 2009), where total mass loads in 
WWTP inﬂuent ranged from 1.5 to 6.7 g/d/1000 inhabitants, while in 
efﬂuents the levels went from 0.32 to 3 g/d/1000 inhabitants. Never- 
theless, a much larger number of pharmaceuticals was included in this 
study (78 against 30, 28 and 13 in Italy, Spain and Sweden, respective- 
ly), which embraced most of the compounds previously reported in lit- 
erature, together with the fact that the WWTPs studied in Italy, Spain 
and Sweden may not be inﬂuenced by discharges from hospitals. They 
only treat domestic and/or industrial wastewaters. The highest total 
mass loads observed in the present study were mainly due to the X-
ray contrast agent iopromide, since from all the studied pharmaceu- 
ticals this compound had a greater impact in the total mass load both 
in WWTP inﬂuent and efﬂuent (around 80–85% of the total mass 
load) (Fig. 1 and Table 2). Nevertheless, the differences pointed out in 
mass loads of WWTP efﬂuents are also related with different consump- 
tion patterns of pharmaceuticals among countries, as well as differences 
in wastewater treatment processes employed in WWTPs or culture 
habits. Comparatively to the highest average daily mass loads of phar- 
maceuticals in WWTP efﬂuents ranked by Verlicchi et al. (2012b), in 
general, the mass loads found in this study were lower than those 
reported in literature, with the exception of sulfamethoxazole, loraze- 
pam and pravastatin. However the highest average mass loads found 
in this study belong to iopromide and valsartan (7241 and 276 mg/d/ 
1000 inhabitants, respectively), two pharmaceuticals not included in 
the cited work (Verlicchi et al., 2012b). 
Other therapeutic classes having high mass loads were antihyper- 
tensives, antibiotics, namely ﬂuoroquinolones and sulfamethoxazole, 
diuretics, non-steroidal anti-inﬂammatory drugs (NSAIDs) and anal- 
gesics (Table 2). Within each group, pharmaceuticals showing higher 
loads in WWTP inﬂuent corresponded to ibuprofen and naproxen for 
NSAIDs (loads up to 661 and 250 mg/d/1000 inhabitants, respective- 
ly); acetaminophen for analgesics (12 to 1058 mg/d/1000 inhabi- 
tants); valsartan and irbesartan for antihypertensives (up to 1146 
and 157 mg/d/1000 inhabitants, respectively); oﬂoxacin and sulfameth- 
oxazole  for  antibiotics  (up to  1292  and 199 mg/d/1000  inhabitants, 
  
respectively); and furosemide for diuretics (from 194 to 614 mg/d/1000 
inhabitants), whereas in efﬂuents the most representative pharma- 
ceuticals were also ibuprofen and ketoprofen for NSAIDs, with 
loads up to 88 mg/d/1000 inhabitants; codeine and   acetaminophen 
for analgesics (highest loads of 41 and 22 mg/d/1000 inhabitants, re- 
spectively); valsartan and irbesartan for antihypertensives (up to 578 
and 90 mg/d/1000 inhabitants); sulfamethoxazole  and  ciproﬂoxacin 
for antibiotics (from 57 to 201 and from 20 to 87 mg/d/1000 inhabitants, 
 
 
 
Fig. 1. Boxplots indicating total mass load values, expressed in mg/day/1000 inhabitants, of some of the most representative therapeutic groups in WWTP inﬂuent and   efﬂuent. 
  
 
 
 
Fig. 1 (continued). 
 
 
respectively); and furosemide for diuretics (from 69 to 252 mg/d/1000 
inhabitants). More detailed information can be found in Supporting 
information. 
Since the efﬂuents of the four hospitals are discharged to the same 
WWTP, their individual impact in the receiving urban wastewaters 
was evaluated. The estimated total mass loading of the most repre- 
sentative therapeutic groups across hospitals based on the seven 
sampling campaigns is presented in Fig. 2. In general, the estimated 
total mass loadings were approximately 306 g d− 1 for university hos- 
pital, 155 g d− 1 for general one, 14 g d− 1 for pediatric and 1.5 g d− 1 
for maternity hospital. Higher daily loads of pharmaceuticals from 
university and general hospitals into urban wastewaters might be 
explained by their dimension comparatively to the other two hospi- 
tals (1456 and 350 beds, respectively), since they have a high con- 
sumption rate of pharmaceuticals and higher water consumption 
(Table S2, Supporting information), which is reﬂected in an increased 
volume of efﬂuents entering the public sewer system as well as their 
greatest contribution into the input of pharmaceuticals to the WWTP 
inﬂuent (Table 3). However, as the WWTP has higher ﬂow rates 
 
than hospitals (Tables S1 and S2, Supporting information); the daily 
mass loads of pharmaceuticals from urban wastewater would be 
greater than those from hospital efﬂuents even that its concentrations 
were, in general, lower. 
The total contribution of hospital efﬂuents into the load of phar- 
maceuticals to urban wastewaters was calculated for the different 
therapeutic groups taking into account the seven sampling campaigns 
performed. Table 3 summarizes the contribution to WWTP inﬂuent 
originated from each hospital relatively to the most representative 
therapeutic groups and more detailed information is given in Supporting 
Information (Tables S9–S12). 
On the whole, the four hospitals contribution varied from approx- 
imately 3.3% for lipid regulators and cholesterol lowering statin 
agents load entering the WWTP to 74% for histamine H2 receptors an- 
tagonists (Table 3). In general, the highest input of pharmaceuticals 
into WWTP inﬂuent was observed in the university hospital (bed 
density = 3.4, Table S3 Supporting information), while the contribu- 
tion of the maternity hospital (bed density = 0.2, Table S3 Supporting 
information) represented less than 1% for all the therapeutic groups. 
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Fig. 2. Estimated total mass loadings of the most representative therapeutic groups to a WWTP inﬂuent from different hospital efﬂuents. Please note that the scale for the x-axis 
(total mass load in mg  d
−1
) change between   boxes. 
 
These ﬁndings might be justiﬁed by the capacity of these two hospi- 
tals, since the former has 1456 beds and the latter only 96, which 
would be reﬂected in their consumption rate of pharmaceuticals as 
well as in their production of wastewaters. However, there was an ex- 
ception for pediatric hospital that had a more marked contribution for 
antihelmintics (20% of the load entering the WWTP). Analgesics, anti- 
biotics and NSAIDs were among the therapeutic groups with highest 
contributions to the total load of pharmaceuticals originating from 
hospital efﬂuents, corresponding to 51, 41 and 32%, respectively. In 
fact, more pronounced contributions were described in literature for 
antibiotics (Beier et al., 2011; Ort et al., 2010; Thomas et al., 2007; 
Verlicchi et al., 2012a), reaching, in some cases, contributions as high 
as 272% (ciproﬂoxacin) (Thomas et al., 2007), 94% (clarithromycin) 
(Beier et al., 2011) or 67% (azithromycin) (Verlicchi et al., 2012a). 
On the other hand, for some of the most consumed analgesics/NSAIDs 
(for instance, ibuprofen, diclofenac or acetaminophen) hospital con- 
tribution reported in literature did not exceed 15% (Beier et al., 
2011; Langford and Thomas, 2009; Thomas et al., 2007; Verlicchi et 
al., 2012a), which is in agreement with our results in what concern 
to ibuprofen and diclofenac (contribution up to 4.2 and 9.5%, respec- 
tively) (data not shown), however for acetaminophen, the contribution 
of university and general hospitals went to 483 and 115%, respectively 
(data not shown). 
Nevertheless, the X-ray contrast agent iopromide, which had a 
mean total mass load of approximately 303 g d− 1 coming from hos- 
pital efﬂuents, only contributed with approximately 13% of its total 
mass load found in WWTP inﬂuent, though Ort et al. (2010) reported 
a minor contribution (less than 5%). These might be explained by the 
fact that iopromide is administered to patients to help in diagnostic 
exams and it would be mainly excreted in their houses entering directly 
in WWTP by urban wastewaters. Nevertheless, it has to be taken into 
account that the concentration of X-ray contrast agents widely varies 
over the day and from one day to another, inﬂuencing the amount of 
iopromide found in hospital efﬂuents and urban wastewaters. 
It is clear that for the most consumed therapeutic classes (analgesics, 
antibiotics and NSAIDs), hospital efﬂuents are an important source of 
input of pharmaceuticals into WWTP, reaching in some cases more 
than 50% of total mass load. However, in general, hospitals contribution 
to the load of pharmaceuticals into urban wastewaters has not a great 
impact, being most of the total load owing to public wastewaters. 
Removal efﬁciency of pharmaceuticals were evaluated by compar- 
ing the load of each pharmaceutical in WWTP inﬂuent and efﬂuent. 
Table 2 shows the total mass loads found for the different therapeutic 
groups (range and mean value), expressed as the sum of all pharma- 
ceuticals belonging to each therapeutic group, as well as their removal 
rates in the studied WWTP, taking into account the seven sampling 
campaigns carried out during this study. Results obtained proved 
that WWTP was not able to completely remove pharmaceuticals. In- 
deed, a great variation in removal efﬁciencies, between the different 
therapeutic groups as well as within each group, was observed, 
going from not eliminated to 99%. However, in terms of mean values, 
removal efﬁciency did not exceed 84%. Analgesics, NSAIDs, the oral 
antidiabetic metformin and ﬂuoroquinolone antibiotics were among 
the  most  efﬁciently  removed,  showing removal  efﬁciencies higher 
University hospital General hospital Paediatric hospital Maternity hospital 
      
  
 
 Table 3 
Contribution, expressed in percentage, to WWTP inﬂuent originating from hospital ef- 
ﬂuents for the most representative therapeutic groups. 
followed, that is HQs were calculated using the highest level detected 
for each pharmaceutical as MEC. HQs were evaluated using three differ- 
   ent trophic levels representative of aquatic ecosystem, namely   algae, 
Therapeutic group Input to WWTP inﬂuent (%) daphnids and ﬁsh, in order to despite differences between the complex 
University 
hospital 
General 
hospital 
Pediatric 
hospital 
Maternity 
hospital 
Total mixture of species present in natural ecosystems (von der Ohe et al., 
2011). 
NSAIDs 21 6.9 4.0 0.4 32 
Analgesics 35 11 4.8 0.4 51 
Figs. 3 and 4 summarizes the HQs obtained for algae, daphnids and 
ﬁsh in hospitals and WWTP wastewaters, respectively. According to 
Lipid regulators and 
cholesterol lowering 
statin agents 
2.7 0.1 0.5 0.01 3.3 the results, algae appeared to be the most sensitive species followed 
by daphnids and ﬁsh, which is in agreement with data reported in 
literature for surface waters (Ginebreda et al., 2010). As   expected, Psychiatric drugs 4.7 1.6 0.5 0.1 6.9 
Histamine H2 receptor 
antagonists 
36 37 0.4 0.3 74 higher HQs were obtained in hospital efﬂuents than in WWTP waste- 
waters. Pharmaceuticals like ciproﬂoxacin, oﬂoxacin and  ibuprofen 
Diuretics 13 5.8 1.1 0.2 20 showed HQs higher than one for all trophic levels, posing a risk   to 
Oral antidiabetics 
(metformin) 
4.3 3.3 0.1 0.2 7.9 algae, daphnids and ﬁsh, therefore it is expected that they might 
Antihypertensives 5.7 0.6 0.2 0.05 6.6 
Calcium channel blockers 7.3 2.5 0.2 0.03 10 
Antibiotics 33 6.8 0.6 0.2 41 
be  a  threat  for  all  aquatic  ecosystem.  Besides  those, iopromide, 
diclofenac, dexamethasone and gemﬁbrozil also pose a risk to ﬁsh, 
while  acetaminophen,  metronidazole,  ketoprofen,   thiabendazole, 
- Fluoroquinolone 
antibiotics 
40 8.3 0.3 0.03 49 salbutamol and propranolol pose an ecotoxicological risk to daphnids. 
On the other hand, besides the above mentioned ﬂuoroquinolone 
- Macrolide antibiotics     41 11 1.0 1.0 54 
- Other antibiotics 21 3.8 1.1 0.1 26 antibiotics, algae showed high sensitivity to others antibiotics, such 
Antiplatelet agent 
(clopidogrel) 
Prostatic hyperplasia 
(tamsulosin) 
26 6.3 0.9 0.2 33 
7.2 2.7 1.1 0.2 11 
sulfamethoxazole, azithromycin and clarithromycin, as well as other 
pharmaceuticals like iopromide, naproxen, ketoprofen, ﬂuoxetine, 
and propranolol. Regarding WWTP efﬂuent, only the antibiotics cipro- 
ﬂoxacin, oﬂoxacin, sulfamethoxazole, azithromycin and clarithromycin 
Anticoagulant (warfarin) 6.0 2.3 0.2 0.05 8.6 
X-ray contrast agent 
(iopromide) 
7.9 5.1 0.07 0.001 13 revealed to pose an ecotoxicological risk for algae (Fig. 4). Nevertheless, 
most of the pharmaceuticals that revealed to pose a risk for algae  in 
    Antihel mintics 1.7 10 20 0.4 32          
 
 
 
than 70%, in contrast to β-blockers, antihelmintics, the antibiotic 
trimethoprim and the β-agonist salbutamol that were not eliminated 
at all. Relatively to antibiotics, differences in their removal efﬁciency 
were observed depending on their group. For instance, ﬂuoro- 
quinolones had the highest removal efﬁciency (70%), while all the 
other groups of antibiotics did not exceed 19%, or were not removed 
at all as was the case of trimethoprim. Our ﬁndings are in agreement 
with previous studies found in the scientiﬁc literature, where incom- 
plete removal of a wide range of pharmaceuticals in conventional 
WWTPs has been described (Castiglioni et al., 2006; Jelic et al., 
2011). Moreover, this was expected since removal of pharmaceuticals 
in conventional WWTP is generally due to the biological treatment, 
where biodegradation/biotransformation and sorption are the two 
main mechanisms occurring in the biological reactors. Therefore, the 
physico-chemical properties of pharmaceuticals, the origin and com- 
position of wastewaters (urban, industrial, hospital, etc.), and the op- 
erational conditions of WWTP, such as biomass, concentration, sludge 
retention time (SRT), hydraulic retention time (HRT), pH, tempera- 
ture, conﬁguration (aerobic, anaerobic and/or anoxic reactors) and 
type of plant are determinant factors for the removal of pharmaceuti- 
cals in conventional WWTPs (Verlicchi et al., 2012b). 
 
3.3. Environmental risk assessment 
 
Nowadays the majority of prioritization lists of pharmaceuticals 
are based on the concept of risk assessment, which takes into account 
the potential effect of a given pharmaceutical and its exposure level 
(Guillén et al., 2012). For that hazard quotients (HQ), which establish 
the ratio between Predicted Environmental Concentration (PEC) and 
Predicted No-Effect Concentration (PNEC), could be a useful tool, as 
was proved by some authors (Ginebreda et al., 2010; Gros et al., 
2010; Verlicchi et al., 2012a). However, the replacement of PEC for 
Measured Environmental Concentration (MEC) allows evaluating 
risks posed by pharmaceuticals in a more realistic scenario. 
In this work, HQs were evaluated according to EU guidelines in both 
hospital and WWTP efﬂuents. An approach of “worst case scenario” was 
WWTP efﬂuent had low removal efﬁciencies or, in some cases, where 
not removed at all, as in the case of ciproﬂoxacin (HQ = 279) (Fig. 4). 
These results indicate that more attention should be paid to the re- 
ceiving waters of WWTP efﬂuents, since pharmaceuticals are being 
discharged into the environment at concentrations that are able to 
pose a threat to aquatic ecosystems, at least to a lower trophic 
level. However, if a lower level of the food chain would be affected, 
this could have a negative impact in the entire aquatic ecosystem. 
In accordance with these ﬁndings, it could be concluded that due to 
the incomplete removal of pharmaceuticals in WWTPs, especially 
some antibiotics, their efﬂuents would represent a threat to aquatic 
ecosystems and probably the dilution of wastewaters in receiving sur- 
face waters may be not enough to mitigate their ecotoxicological risk. 
Indeed, the mitigation of the risk posed by the occurrence of pharma- 
ceuticals in the treated efﬂuent is due to not only dilution of the re- 
ceiving water body but also to auto-depurative processes occurring 
within the water phase in the bulk of the receiving water body, as 
well as photocatalytic processes once pharmaceuticals reach the envi- 
ronment and remain in the free water systems (rivers, lakes, sea, etc.). 
It was also observed that the detection of high concentrations of a 
pharmaceutical in the environment did not necessarily imply an envi- 
ronmental risk. For example, a high concentration of acetaminophen 
was found in WWTP efﬂuent (Table 2), but did not pose a risk for 
daphnids (HQ b 1) (Fig. 4). Therefore, besides the consumption rate 
of pharmaceuticals, risk assessment studies should be taken into ac- 
count, in order to prioritize the compounds to be monitored. 
Based on the analytical and ecotoxicological data reported in this 
study, a list of 10 pharmaceuticals potentially dangerous for the 
aquatic organisms could be delineated for hospital and WWTP efﬂu- 
ents, based on HQs, in order to being considered for further inclusion 
in monitoring programs or even in future regulations. The proposed 
list for WWTP efﬂuents should include the antibiotics ciproﬂoxacin, 
oﬂoxacin, sulfamethoxazole, azithromycin and clarithromycin, since 
they showed to pose an ecotoxicological risk to algae (HQ > 1); the 
X-ray contrast agent iopromide due to its high concentration in 
WWTP efﬂuents (34–85 μg L−1) together with HQs close to the unit 
to algae and ﬁsh; the NSAIDs ibuprofen and diclofenac given that they 
may be potential harmful to ﬁsh, especially diclofenac (HQ = 0.9); 
and ﬁnally the SSRI ﬂuoxetine and its human metabolite norﬂuoxetine, 
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Fig. 4. Hazard quotients of WWTP efﬂuent for: a) Fish; b) Daphnid; c) Algae. 
 
 
only pharmaceutical included in a top 20 priority ranking based on eco- 
logical effects deﬁned by Kumar and Xagoraraki (2010). Another study 
that ranking the potential impact of 98 frequently detected pollutants, 
including 38 pharmaceuticals and 10 metabolites, also showed that 
the impact of WWTP efﬂuent in receiving surface waters is mainly due 
to ﬂuoxetine and ciproﬂoxacin (Muñoz et al., 2008), two of the pharma- 
ceuticals included in our proposed list for WWTP efﬂuents. 
Nevertheless, it should bear in mind that the type of water has also 
effect in the ranking of pharmaceuticals (Kumar and Xagoraraki, 
2010), justifying the development of different prioritization lists of 
pharmaceuticals in agreement with the kind of water sample that is 
being considered. 
The approach followed in this work is only focused on the ecotoxicity 
that individual pharmaceuticals may cause to aquatic organisms. How- 
ever, in the aquatic environment they are present as a mixture of differ- 
ent therapeutic groups, their metabolites and transformation products, 
which may have synergic or additive effects, exhibiting higher toxicities 
than single compounds, even at lower concentrations, as was shown by 
some authors (Cleuvers, 2003, 2004; DeLorenzo and Fleming, 2008; 
Quinn et al., 2009). 
 
4. Conclusions 
 
Higher concentrations of pharmaceuticals were found in hospital 
efﬂuents than in WWTP inﬂuent; however such high levels in hospital 
efﬂuents did not imply the same high contribution in terms of mass 
loads due to the much lower ﬂow of hospital efﬂuents compared to 
total WWTP inﬂuent ﬂow. 
The contribution of hospital efﬂuents entering the receiving 
WWTP inﬂuent varied in a wide range among the different therapeu- 
tic groups and from hospital to hospital, reaching in some cases more 
than 50% of total input. NSAIDs, analgesics and antibiotics are amongst 
the groups with highest loads coming from hospitals, whereas antihy- 
pertensives, psychiatric drugs or lipid regulators do not have a very 
signiﬁcant contribution (b 10%), being most of the input of these kind 
of pharmaceuticals attributed to public wastewaters. Contribution of 
hospitals with a higher number of beds is also more pronounced com- 
paratively to small hospitals. 
Removal efﬁciencies of pharmaceuticals in WWTP varied from 
more than 90% for compounds like the analgesic acetaminophen 
and the NSAIDs salicylic acid and ibuprofen, to no removal at all for 
 
β-blockers, antihelmintics and salbutamol, proving that the waste- 
water treatment applied is not able to efﬁciently remove a large 
number of pharmaceuticals. As a consequence, WWTP efﬂuents are 
discharging pharmaceuticals into receiving surface waters, being one 
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of the most important contributors to their environmental load. In 
the present work, a total mass load between 5 and 14 g/d/1000 in- 
habitants in WWTP efﬂuent was reported. 
Environmental risk assessment posed by the pharmaceuticals 
found in hospital efﬂuents and WWTP wastewaters was evaluated 
at three different trophic levels (algae, daphnids and ﬁsh). In hospital 
wastewaters, ciproﬂoxacin, oﬂoxacin and ibuprofen revealed to pose 
a risk to all trophic levels, which is related to their high measured 
concentrations. In terms of high risk for the environment, more atten- 
tion should be paid to antibiotics (ﬂuoroquinolones, macrolides and 
sulphonamides), given that they showed HQs higher than the unit 
in WWTP efﬂuent for algae, which were the most sensitive species 
for the majority of pharmaceuticals. Prioritization of environmental 
risk assessment stated in this work was only established taking into 
account individual acute toxicity data. Nevertheless, synergic or addi- 
tives effects should be considered, since this is a more realistic scenario. 
Furthermore, two lists of pharmaceuticals potentially dangerous 
for the environment were proposed, taking into account both hospital 
and WWTP efﬂuents. For the former, pharmaceuticals like ciproﬂoxa- 
cin, oﬂoxacin, sulfamethoxazole, azithromycin, clarithromycin, met- 
ronidazole, ibuprofen, acetaminophen, ﬂuoxetine and iopromide, 
which have HQs higher than the unit should be considered, while 
for WWTP efﬂuents, the list embraces pharmaceuticals such as cipro- 
ﬂoxacin, oﬂoxacin, sulfamethoxazole, azithromycin, clarithromycin, 
ﬂuoxetine and its human metabolite norﬂuoxetine, iopromide, ibu- 
profen and diclofenac, which are potentially dangerous to aquatic 
organisms, and should be included in further monitoring programs. 
The proposed list of pharmaceuticals highlights the importance of 
extending, in the future, the monitoring studies to metabolites. 
This data suggests that authorities and scientiﬁc community 
should improve the co-treatment of hospital and urban wastewaters, 
since the former have a high concentration of contaminants and con- 
ventional WWTPs are unable to efﬁciently remove pharmaceuticals 
and evaluate the use of alternative treatments for a better manage- 
ment of hospital wastewaters. 
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